Skip to main content
main-content

12.04.2019 | Clinical Study | Ausgabe 2/2019

Journal of Neuro-Oncology 2/2019

Evaluation of pediatric glioma outcomes using intraoperative MRI: a multicenter cohort study

Zeitschrift:
Journal of Neuro-Oncology > Ausgabe 2/2019
Autoren:
Michael Karsy, S. Hassan Akbari, David Limbrick, Eric C. Leuthardt, John Evans, Matthew D. Smyth, Jennifer Strahle, Jeffrey Leonard, Samuel Cheshier, Douglas L. Brockmeyer, Robert J. Bollo, John R. Kestle, John Honeycutt, David J. Donahue, Richard A. Roberts, Daniel R. Hansen, Jay Riva-Cambrin, Garnette Sutherland, Clair Gallagher, Walter Hader, Yves Starreveld, Mark Hamilton, Ann-Christine Duhaime, Randy L. Jensen, Michael R. Chicoine
Wichtige Hinweise

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s11060-019-03154-7) contains supplementary material, which is available to authorized users.
Michael Karsy and S. Hassan Akbari have contributed equally to this work.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abstract

Background

The use of intraoperative MRI (iMRI) during treatment of gliomas may increase extent of resection (EOR), decrease need for early reoperation, and increase progression-free and overall survival, but has not been fully validated, particularly in the pediatric population.

Objective

To assess the accuracy of iMRI to identify residual tumor in pediatric patients with glioma and determine the effect of iMRI on decisions for resection, complication rates, and other outcomes.

Methods

We retrospectively analyzed a multicenter database of pediatric patients (age ≤ 18 years) who underwent resection of pathologically confirmed gliomas.

Results

We identified 314 patients (mean age 9.7 ± 4.6 years) with mean follow-up of 48.3 ± 33.6 months (range 0.03–182.07 months) who underwent surgery with iMRI. There were 201 (64.0%) WHO grade I tumors, 57 (18.2%) grade II, 24 (7.6%) grade III, 9 (2.9%) grade IV, and 23 (7.3%) not classified. Among 280 patients who underwent resection using iMRI, 131 (46.8%) had some residual tumor and underwent additional resection after the first iMRI. Of the 33 tissue specimens sent for pathological analysis after iMRI, 29 (87.9%) showed positive tumor pathology. Gross total resection was identified in 156 patients (55.7%), but this was limited by 69 (24.6%) patients with unknown EOR.

Conclusions

Analysis of the largest multicenter database of pediatric gliomas resected using iMRI demonstrated additional tumor resection in a substantial portion of cases. However, determining the impact of iMRI on EOR and outcomes remains challenging because iMRI use varies among providers nationally. Continued refinement of iMRI techniques for use in pediatric patients with glioma may improve outcomes.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
Supplementary Figure S1: Distribution of age and tumor size for cohort. A) Patient age and B) tumor size approximate normal distributions (TIF 3943 KB)
11060_2019_3154_MOESM1_ESM.tif
Supplementary Figure S2: Evaluation of overall survival (OS) depending on WHO grade for cohort. Evaluation of OS for WHO grade A) I, B) II, C) III, and D) IV tumors is shown. No significant difference in OS was seen based on WHO grade. (TIF 2663 KB)
11060_2019_3154_MOESM2_ESM.tif
Supplementary Figure S3: Evaluation of progression-free survival (OS) depending on WHO grade for cohort. Evaluation of PFS for WHO grade A) I, B) II, C) III, and D) IV tumors is shown. No significant difference in PFS was seen based on WHO grade (TIF 2824 KB)
11060_2019_3154_MOESM3_ESM.tif
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 2/2019

Journal of Neuro-Oncology 2/2019 Zur Ausgabe
  1. Sie können e.Med Neurologie & Psychiatrie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  2. Sie können e.Med Neurologie 14 Tage kostenlos testen (keine Print-Zeitschrift enthalten). Der Test läuft automatisch und formlos aus. Es kann nur einmal getestet werden.

  3. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise